cisplatin + etoposide + filgrastim

This is a combination regimen consisting of cisplatin, etoposide, and filgrastim. Cisplatin is a platinum-based chemotherapeutic agent that forms DNA crosslinks and induces apoptosis in rapidly dividing cells. Etoposide is a topoisomerase II inhibitor that causes DNA strand breaks and prevents cell division. Filgrastim is a recombinant human granulocyte colony-stimulating factor (G-CSF) used to stimulate the production of neutrophils, reducing the risk of neutropenia associated with chemotherapy. This combination is primarily used in the treatment of various cancers such as germ cell tumors and lung cancer, where filgrastim supports chemotherapy by mitigating myelosuppression and enabling delivery of full-dose chemotherapy[1][2][3].